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Abstract
Glucocorticoids are necessary for life after birth and regulate
numerous homeostatic functions in man, including glucose
homeostasis, protein catabolism, skeletal growth, respiratory
function, inflammation, development, behavior, and apopto-
sis. In a clinical setting, they are widely used as anti-inflam-
matory agents to control both acute and chronic inflam-
mation. Unfortunately, owing to their broad range of physi-
ological actions, patients treated with glucocorticoids for
long periods of time experience a variety of serious side
effects, including metabolic syndrome, bone loss, and psy-
chiatric disorders including depression, mania, and psycho-
sis. Our understanding of how one hormone or drug regulates
all of these diverse processes is limited. Recent studies have
shown that multiple glucocorticoid receptor isoforms are pro-
duced from one gene via combinations of alternative mRNA
splicing and alternative translation initiation. These isoforms
possess unique tissue distribution patterns and transcriptional
regulatory profiles. Owing to variation in the N-terminal and
C-terminal length of glucocorticoid receptor isoforms, dif-
ferent post-translational modifications including ubiquitina-
tion, phosphorylation, and sumoylation are predicted,
contributing to the complexity of glucocorticoid signaling.
Furthermore, increasing evidence suggests that unique glu-
cocorticoid receptor isoform compositions within cells could
determine the cell-specific response to glucocorticoids. In
this review, we will outline the recent advances made in the
characterization of the transcriptional activity and the selec-
tive regulation of apoptosis by the various glucocorticoid
receptor isoforms.
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Introduction
Glucocorticoids are steroid hormones that are produced and
released by the adrenal gland under the control of the hypo-
thalamic-pituitary-adrenal (HPA) axis. In response to a vari-
ety of stressors, the hypothalamus releases corticotropin-
releasing hormone and vasopressin that stimulates the release
of adrenocorticotropic hormone (ACTH) from the pituitary
gland (1). In the adrenal cells, ACTH stimulates the produc-
tion and release of glucocorticoids into the bloodstream,
affecting all tissues within the body. Their actions are medi-
ated by the ubiquitous cytoplasmic glucocorticoid receptor,
which functions as a hormone-activated transcription factor
of glucocorticoid target genes. They are important for the
maintenance of diverse biological activities such as the reg-
ulation of vascular tone, homeostasis of the central nervous
system, intermediary metabolism, and water/electrolyte bal-
ance. In addition, glucocorticoids exert potent anti-inflam-
matory and immunomodulatory effects, and are therefore
commonly used in the treatment of chronic inflammatory and
autoimmune diseases. They are also included in chemother-
apeutic regimens for the treatment of leukemia, lymphomas,
and myelomas due to their ability to induce lymphocyte
apoptosis (2–5).
Synthetic derivatives of glucocorticoids have been applied
successfully in a clinical setting for more than half a century
(6–8). Although they are considered to be relatively inex-
pensive drugs, synthetic glucocorticoids are believed to
account for a $10 billion (USD) per year market (9). How-
ever, their use is limited by serious adverse effects such as
diabetes, osteoporosis, myopathy, suppression of the HPA
axis, and growth retardation (9). Osteoporosis, for instance,
is one of the side effects that can be life-threatening (10). In
prolonged glucocorticoid exposure (treatment for 6 months,
for example), the incidence of osteoporosis can be as high
as 50%, accounting for approximately 25% of cases of
osteoporosis. This is a serious problem especially in elderly
patients (70–79 years of age) because they frequently receive
glucocorticoids prescribed at high-doses ()7.5 mg/day) for
long periods of time ()2 years) (10, 11).
Glucocorticoid resistance is another major problem that
appears in patients receiving synthetic glucocorticoids for the
treatment of inflammatory diseases (12–14). Although glu-
cocorticoids are highly effective in the control of asthma and
other chronic inflammatory or immune diseases, a small pro-
portion of patients with asthma fail to respond to treatment
(even to high-doses of oral glucocorticoids), and patients
with chronic obstructive pulmonary disease are generally
unresponsive to glucocorticoids (15). In addition, renal trans-
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Figure 1 Linear schematic of the human glucocorticoid receptor (hGR) protein and generation of multiple GR isoforms from a single
gene. The three major domains, the N-terminal domain (NTD), DNA-binding domain (DBD), and the ligand binding-domain (LBD) of
hGR are shown. As discussed and referenced in the text, approximate locations are indicated of some defined regions and functions
concerning the AF-1 (activation function 1), the AF-2 (activation function 2) helix, and cofactor/chaperone binding.
planted patients receiving steroid therapy also develop glu-
cocorticoid resistance, most likely due to alterations in the
expression levels of the glucocorticoid receptor detected in
the lymphocytes of these patients (16). Therefore, there is a
great medical need for glucocorticoid-like compounds that
possess anti-inflammatory and immunomodulatory proper-
ties, yet display a reduced risk of side effects and resistance.
Recently, several strategies for development of novel glu-
cocorticoids or glucocorticoid substitutes with an improved
therapeutic index have been pursued by different pharma-
ceutical companies and research groups (8). For example,
chemical optimization of compounds has been done to
improve activity, to generate prodrugs that have enhanced
bioavailability, to release the compounds in target tissues, or
to generate novel glucocorticoid ligands, such as selective
glucocorticoid receptor agonists (SEGRAs). SEGRAs pref-
erentially induce transrepression of glucocorticoid regulated
genes (responsible for the anti-inflammatory effects of glu-
cocorticoids) with little or no transactivating activity (sug-
gested to be involved with the development of side effects)
(8, 17). Although, the selective agonist receptors are cur-
rently in Phase II clinical trials, as an alternative topical treat-
ment for atopic dermatitis and inflammation following
cataract surgery (18, 19), it remains to be seen whether selec-
tive receptor agonists cause significantly less side effects
than classical corticoids in clinical applications, such as oral
administration. Furthermore, some of the glucocorticoid-like
compounds identified have undesired effects after prolonged
treatment in vivo (20–22), highlighting the need for further
research to better understand the mechanism of action of
glucocorticoids.
To understand the molecular basis of glucocorticoid-
induced side effects and resistance, it is necessary to obtain
an understanding of their actions in homeostatic signaling
processes. Multiple factors in the glucocorticoid signaling
system such as ligand availability, ultradian hormone pulsing,
alternative splicing of the glucocorticoid receptor, promoter
association, attraction of cofactors, and clearance of recep-
tors from target genes can influence the ultimate transcrip-
tional activity of the glucocorticoid receptor (23, 24). Recent
data from our laboratory suggest that multiple glucocorticoid
receptor isoforms are generated from the primary glucocor-
ticoid receptor transcript through alternative initiation of
translation. Furthermore, the glucocorticoid receptor trans-
lational isoforms are expressed in a tissue specific manner
and regulate distinct genes (25, 26). This could represent a
general mechanism that confers target-tissue sensitivity to
glucocorticoid hormones. This discovery could help to
explain why patients taking glucocorticoids frequently devel-
op serious adverse effects and resistance, and increase the
possibility of new targets for the development of selective
glucocorticoid receptor isoforms agonists.
The glucocorticoid receptor: modular
organization, mechanism of action, and
transcriptional regulation
The glucocorticoid receptor is a member of the nuclear
receptor superfamily of transcription factors and is ubiqui-
tously expressed at a density varying from 2000 to 30,000
receptors per cell according to the cell type and tissue ana-
lyzed (27–29). The glucocorticoid receptor gene is conserved
from Xenopus to human (30) and encodes a modular protein
organized into three major functional domains: the N-ter-
minal domain (NTD), the central DNA-binding domain
(DBD), and the C-terminal ligand-binding domain (LBD)
(Figure 1). When compared to other steroid hormone recep-
tors, the NTD is poorly conserved in terms of size and
sequence homology, with the exception of a region rich in
negatively charged acidic amino acids known as AF-1 (acti-
vation function 1). The AF-1 region has the ability to activate
target genes in a hormone-independent manner (31, 32) and
has been shown to interact directly with the basal transcrip-
tional machinery as well as with cofactors that participate in
transcriptional regulation. For example, the AF-1 domain
recruits the multimeric chromatin-remodeling ATPase brah-
ma-related gene 1, a homolog of yeast SWI/SNF, that in turn
assembles the histone acetylases P/CAF and CBP/p300 and
facilitates the initiation of transcription (33, 34). Adjacent to
the AF-1 region is the highly conserved DBD. The DBD is
organized into two zinc fingers that contain four cysteines
per loop (34). Specific amino acid sequences within the first
zinc finger mediate the interaction of the glucocorticoid
receptor with specific DNA elements termed glucocorticoid
response elements (GREs). The second zinc finger region
stabilizes the glucocorticoid receptor/GRE interaction (34).
Finally, the C-terminal LBD is highly conserved among ster-
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oid receptors and is essential for hormone binding. The LBD
contains sequences for interaction with heat shock proteins
(HSPs) and nuclear transcription factors. The glucocorticoid
receptor-HSP90 interaction promotes proper folding of the
receptor and prevents the receptor from binding to DNA in
the absence of hormone (20, 35). The LBD also contains a
second transactivation domain termed AF-2. Upon hormone
binding, the glucocorticoid receptor LBD undergoes confor-
mational changes that facilitate the interaction of AF-2 with
members of the p160 family of coactivators (36). A number
of these p160 factors such as steroid receptor coactivator-1,
nuclear receptor coactivator-2, and nuclear receptor coacti-
vator-3 possess histone acetylase activity, which leads to dis-
ruption of nucleosomes and facilitates recruitment of RNA
polymerase II (33).
Multiple mechanisms of glucocorticoid receptor action
have been described, most of which involve the regulation
of gene transcription. In addition, the ligands for the gluco-
corticoid receptor both natural and synthetic are subjected to
pre-receptor metabolism (24). The basic mechanism for reg-
ulating gene transcription by glucocorticoids involves a com-
plex and ever growing network directed by the molecular
structure of the glucocorticoid receptor and interaction with
other proteins such as coregulators, transcription factors, and
other components of the transcription machinery. The glu-
cocorticoid receptor in its inactive form (ligand-free) is locat-
ed in the cytoplasm of cells and is associated with molecular
chaperones and immunophilins. Upon hormone binding, the
glucocorticoid receptor undergoes conformational changes
and dissociates from accessory proteins, which leads to
importin-mediated translocation to the nucleus as a monomer
or dimer through the nuclear pore (Figure 2) (3). In the
nucleus, ligand-activated glucocorticoid receptor dimers
directly interact with GREs in many regions of glucocorti-
coid target genes, including the promoter or enhancer region,
intronic and 59UTR region (37). Alternatively, ligand acti-
vated glucocorticoid receptor dimers as well as monomers
interact with other transcription factors to influence the trans-
cription of genes (38).
Glucocorticoids regulate the expression of a wide array of
target genes by both positive and negative regulatory mech-
anisms. Activation of gene transcription is mediated by posi-
tive GREs. This mechanism has been identified for a large
variety of genes, such as the genes encoding the enzymes
tyrosine aminotransferase and phosphoenolpyruvate car-
boxykinase (PEPCK) (39), and is postulated to be respon-
sible for numerous side effects of glucocorticoids (9).
GRE-bound glucocorticoid receptors selectively recruit sev-
eral transcriptional activators, such as p300, cAMP-respon-
sive element (CRE) binding protein (CREB)-binding protein
(CBP), and p160 nuclear receptor regulators (Figure 2A).
The interaction with coactivators facilitates the transmission
of signals from the glucocorticoid receptor-ligand complex
to the transcription initiation complex. For example, co-
activators possessing intrinsic histone acetyltransferase or
methyltransferase activity alter chromatin structure and
enhance binding of the transcriptional machinery compo-
nents such as transcription factors and RNA polymerase II
to DNA (40). In addition, the transcriptional activity of glu-
cocorticoid receptors is modulated through direct protein-
protein interaction with other transcription factors at the
so-called composite response element. For example, gluco-
corticoid receptor mediated upregulation of PEPCK involves
the cooperative interaction of the glucocorticoid receptor and
CREB with the GRE and (CREB response element) CRE
located in the vicinity of the PEPCK gene, thereby inducing
transactivation (41) (Figure 2B). However, glucocorticoid
receptors can also repress gene transcription through cross-
talk at composite elements. The transcription of the gluta-
thione S-transferase A2 (GSTA2) gene is repressed by the
binding of the glucocorticoid receptor to GRE-like sequence
within the GSTA2 promoter. The repression is mediated by
recruitment of the transcriptional corepressor silencing medi-
ator of retinoic acid and thyroid hormone receptors and sub-
sequent inactivation of CCAAT/enhancer binding protein b
(C/EBPb) and NF-E2-related factor 2 (Nrf2) transcription
factors (42) (Figure 2B). Gene transcription can also be
inhibited by glucocorticoids via interaction of ligand-acti-
vated glucocorticoid receptor with negative GREs (nGREs).
The mechanism of glucocorticoid receptor transcriptional
repression through nGREs is unclear. It has been suggested
that the glucocorticoid receptor can sterically hinder the
binding of positively acting transcription factors to elements
that overlap the nGRE. A classical example of such crosstalk
is the negative regulation of the osteocalcin gene by gluco-
corticoids. The GRE overlaps with the osteocalcin TATA box
and prevents the binding of the general transcription factor
IID resulting in repression of transcription (43) (Figure 2C).
Alternatively, the glucocorticoid receptor also represses gene
transcription through direct interaction with transcription fac-
tors independent of chromatin interaction (Figure 2D). This
crosstalk appears to be the predominant mechanism for the
potent anti-inflammatory actions of glucocorticoids and it
has been described for several transcription factors such as
activator protein 1 (AP-1), nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), MAD (mothers
against decapentaplegic, Drosophila) homolog (Smad), sig-
nal-transducer and activator of transcription protein (STAT)
and interferon regulatory factor (IRF3) (44, 45). Thus, glu-
cocorticoid receptor transcriptional activity is a dynamic pro-
cess that depends on several factors such as the GRE type,
the promoter/enhancer, and its interaction with numerous
coactivators/repressors and transcription factors.
Glucocorticoid receptor splice variants and
N-terminal isoforms
The human glucocorticoid receptor (hGR) is the product of
one gene located on chromosome 5 and consists of nine
exons. Exon 1 and the first part of exon 2 contain the 59UTR,
exons 2–9 contain the protein-coding sequences, and the
39UTR is found within the latter part of exon 9 (30). Through
alternative promoter usage and splicing of pre-mRNA one
gene gives rise to several isoforms that have been designated
hGRa, hGRb, hGRA, hGRP, hGRg, and hGR-low sensitiv-
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Figure 2 Mechanisms of glucocorticoid receptor signaling within cells. 1) Passive diffusion of glucocorticoids into the cell; 2) glucocor-
ticoids are subject to pre-receptor metabolism by 11b-hydroxysteroid dehydrogenase-2 (11b-HSD2); 3) binding of glucocorticoids to the
cytosolic glucocorticoid receptor; 4) dissociation of the glucocorticoid receptor from chaperones; and 5) translocation of the glucocorticoid
receptor to the nucleus and regulation of gene transcription in four different ways: (A) interaction with glucocorticoid response elements
(GREs), (B) interaction with negative GRE (nGRE), (C) interaction with GRE and transcription factors (TFs) at the composite response
elements, and (D) direct interaction with TFs independent of chromatin interaction. TF-RE, transcription factor responsive element; nGRE,
negative glucocorticoid response element; GR-Iso, glucocorticoid receptor isoform; HPS, heat shock protein.
ity. Their distribution and transactivation potential varies bet-
ween tissues, cell lines, and physiological condition/patho-
logical states (46). The most abundant and well-known iso-
form is the classic hGRa. The hGRa and hGRb mRNA
transcripts are generated by alternative splicing of exon 9
(Figure 3) (47, 48). Sequence analysis revealed that although
hGRa and hGRb isoforms are identical up to amino acid
727, hGRa contains an additional 50 amino acids, whereas
hGRb contains an additional, unique 15 amino acids. hGRb
is expressed in a variety of human tissues and cells but at
lower levels when compared to hGRa. However, hGRb is a
very abundant species in certain epithelial cells (49). In con-
trast to hGRa, hGRb resides in the nucleus of cells inde-
pendent of glucocorticoid treatment and is unable to be
activated by endogenous glucocorticoids due to the unique
C-terminal LBD (3).
The physiological role of hGRb is not completely under-
stood. hGRb is thought to affect gene transcription primarily
by acting as a dominant negative of hGRa, thereby inhibiting
the ability of hGRa to signal (50–55). In some clinical con-
ditions such as rheumatoid arthritis, systemic lupus ery-
thematosus, or ulcerative colitis, the increase of hGRb
expression in inflammatory cells has been associated with
glucocorticoid resistance (55, 56). In addition, high levels of
hGRb protein have been reported in T cells in the airway,
peripheral blood mononuclear cells, and in tuberculin-
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Figure 3 Alternative splicing of exon 9 generates GRa and GRb. GRa mRNA produces additional isoforms as a result of alternative
translation initiation. Translation can be initiated at each of the AUG codons corresponding to methionines at positions 1, 27, 86, 90, 98,
316, 331, and 336 of the GR N-terminal domain resulting in a set of hGR isoforms with different lengths, sizes, and functional domains.
Each GR protein is subjected to post-translational modifications by phosphorylation (P) at residues S113, S141, S203, S211, S226, and
S404, SUMOylation (S) at residues K277, K293, and K703, and ubiquitination (u) at residue K417.
induced inflammatory lesions in glucocorticoid-insensitive
asthmatics (5, 14, 57). Interestingly, a recent study from our
group suggests a novel physiological role for hGRb. In un-
stimulated U2 OS osteosarcoma cells stably expressing
hGRb, GRb was found to regulate the expression of over
5000 genes. Thus, hGRb can act not only as a dominant
negative to hGRa but also as an endogenous manipulator of
gene expression under basal conditions. Moreover, an addi-
tional 997 genes were regulated by hGRb in the presence of
the glucocorticoid receptor antagonist RU-486, suggesting
that RU-486 acts as an exogenous ligand for hGRb (58).
This observation highlights the potential for development of
GRb-selective ligands.
Recently, our laboratory has revealed cell-specific expres-
sion of multiple translational hGRa isoforms (25). The GRa
variant mRNA is translated into multiple GRa isoforms
(GRa-A, GRa-B, GRa-C1-2-3, and GRa-D1-2-3) from at
least eight initiation sites through mechanisms involving
ribosomal leaky scanning or ribosomal shunting (Figure 3).
The expression pattern of endogenous translational GRa iso-
forms was determined using multiple glucocorticoid receptor
selective antibodies. The GRa isoforms were found to be
expressed in different cell lines and tissues of rats, mice, and
in human primary cultures of trabecular meshwork cells (25,
59, 60). However, the relative expression levels vary consid-
erably among tissues. For example, in spleen of CD1 mouse,
the amount of GRa-D isoform was similar to GRa-A, -B
and -C isoforms, whereas in bone and in C2C12 myotube
cells (59), the amount of GRa-D isoform is lower when
compared to the other isoforms. The GRa (A–D) isoforms
bind to w3Hx dexamethasone and have similar apparent Kd
values (26) (Table 1). In the absence of glucocorticoids, the
GRa isoforms, except the D isoform, localize to the cyto-
plasm, and as expected, after hormone treatment, the GRa
translational forms A–C translocate to the nucleus (25).
Another interesting difference among the GRa isoforms
lies in their transcriptional activity. The GRa isoforms dis-
play distinct transactivation or transrepression patterns on
global gene expression as examined by cDNA microarray
analyses using cells lines that stably express the different
translational forms. Almost 500 genes in U2 OS cells are
commonly regulated by the GRa isoforms and each of the
isoforms regulates an additional unique set of genes (Table 1)
(26). To determine the DNA binding ability of each isoform,
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Table 1 Glucocorticoid receptor alpha (GRa) isoforms.
GRa-A GRa-B GRa-C3 GRa-D3
AUG codon (25) 1 27 98 336
Translational mechanism (25) Ribosomal scanning Ribosomal leaky Ribosomal leaky Ribosomal shunting
(first start codon) scanning scanning
Ribosomal shunting Ribosomal shunting
Amino acid peptide size (25) 777 751 680 442
Molecular weight (25) 94 kDa 91 kDa 82–84 kDa 53–56 kDa
Subcellular localization (25) ALscytoplasm ALscytoplasm ALscytoplasm ALsnucleus
PLsnucleus PLsnucleus PLsnucleus PLsnucleus
Binding to w3Hx (25) 13.33"7.6 11.28"4.51 8.7"1.83 9.06"1.73
dexamethasone
Kd (nM"SEM)
Binding to GRE in the ATP4sPL ATP4sPL ATP4sPL ATP4sPL
promoter region of GC VDRsPL VDRsPL VDRsPL VDRsAL and PL
regulated genes (25) I-kBasPL I-kBasPL I-kBasPL I-kBasAL and PL
CASP6sPL CASP6sPL CASP6sPL CASP6sPL
GZMAsPL GZMAsPL GZMAsPL GZMAsPL
Ligand-dependent recruitment (–) CBP (–) CBP (≠) CBP (x) CBP
of cofactors to the promoter (–) P300 (–) P300 (≠) P300 (x) P300
region of the GZMA gene (–) (A)H4 (–) (A)H4 (≠) (A)H4 (x) (A)H4
(26) (–) (p)Pol II (–) (p)Pol (≠) (p)Pol (x) (p)Pol




Gene regulation profile (no. 3451 2945 3252 1761
of genes from Agilent whole
human arrays) (26)
Half-life of GR isoforms (25) ALs12–15 h ALs12–15 h ALs12–15 h ALs12–15 h
PLs6 h PLs6 h PLs6 h PLs6 h
Cell expression (human) HeLa, A549, CEM HeLa, A549, CEM HeLa, A549, CEM HeLa, A549, CEM
(25, 58) cells and primary cells and primary cells and primary cells and primary
trabecular meshwork trabecular meshwork trabecular meshwork trabecular meshwork
cells cells cells cells
Tissue expression (mouse Liver, brown fat, Liver, brown fat, Liver, brown fat, Liver, brown fat,
and rat) (25) esophagus, stomach, esophagus, stomach, esophagus, stomach, esophagus, stomach,
colon, heart, aorta, colon, heart, aorta, colon, heart, aorta, colon, heart, aorta,
spleen, thymus, lung, spleen, thymus, lung, spleen, thymus, lung, spleen, thymus, lung,
bladder bladder bladder bladder
Induction of apoptosis (–) Propidium iodide (–) Propidium iodide (≠) Propidium iodide (x) Propidium iodide
(dexamethasone positive positive positive positive
100 nM–48 h) (26) (–) Annexin positive (–) Annexin positive (≠) Annexin positive (–) Annexin positive
and PI negative and PI negative and PI negative and PI negative
(–) Activated PARP (–) Activated PARP (≠) Activated PARP (–) Activated PARP
(–) DNA degradation (–) DNA degradation (≠) DNA degradation (x) DNA degradation
(–) Caspase activation (–) Caspase activation (≠) Caspase activation (x) Caspase activation
AL, absence of ligand; PL, presence of ligand; –, no change related to wild type; ≠, significant increase related to wild type;
x, significant decrease related to wild type; ATP4, adenosine 59-triphosphate 4; VDR, vitamin D receptor; I-kBa, nuclear factor of kappa
light polypeptide gene enhancer in B cells inhibitor, alpha; CASP6, caspase 6; GZMA, granzyme A; CBP, cAMP-responsive element
(CRE) binding protein (CREB)-binding protein; (A)H4, acetylated histone H4; (p)Pol II, RNA polymerase II; PI, propidium iodide;
PARP, poly (ADP-ribose) polymerase.
chromatin immunoprecipitation (ChIP) assays using GRa-
selective antibodies were performed. Results indicate that
upon ligand binding the GRa (A–D) isoforms have similar
binding affinities for the GREs found in the ATPase, Hq/
Kq exchanging, alpha polypeptide (ATP4A), vitamin D
receptor (VDR), nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha (I-kBa), caspase-6
(CASP6), and granzyme A (GZMA) genes. However, the
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GRa-D isoform was found to bind to certain promoters (e.g.,
VDR and I-kBa) even in the absence of ligand. In addition,
another subset of ChIP assays revealed that the individual
GRa isoforms differ in their ability to recruit cofactors, mod-
ify chromatin, and recruit active RNA polymerase, and these
differences seem to be gene specific. For example, signifi-
cantly higher amounts of CBP and p300 were recruited to
the GZMA promoter region by the GRa-C isoform (26).
Thus, these experiments provide important evidence sug-
gesting that the GRa isoforms are inherently different pro-
teins that differentially transduce glucocorticoid hormone
signals.
Selective regulation of apoptosis by GR
isoforms
The physiological consequence of differential expression of
GRa isoforms was evaluated in a model of dexamethasone-
induced apoptosis in U2 OS cells stably transfected with the
individual translational GRa isoforms. Cell death and mark-
ers of apoptosis such as the externalization of phosphatidyl
serine, PARP cleavage, DNA degradation, and caspase activ-
ity, were induced by hormone in a GRa isoform-selective
manner (Table 1). Cells expressing the isoform C3 have ele-
vated levels of apoptotic markers and are more sensitive to
dexamethasone-induced apoptosis when compared to the
other isoforms A, B, and D3. The D3 isoform expressing
cells are relatively resistant to glucocorticoid-induced apop-
tosis. Consistent with this observation, the GRa isoforms
regulate cell death-related genes in a selective manner. Fur-
thermore, many of the genes involved in apoptosis, such as
caspase-6 and -7, tumor necrosis factor (TNF) receptor
superfamily members, and caspase recruitment domain anti-
apoptotic genes are regulated by at least one of the transla-
tional GRa isoforms (26). These novel findings suggest the
GRa isoforms display distinct apoptotic-inducing activities
by selectively regulating genes involved in apoptosis and
strengthen the idea of tissue-specific expression of GRa iso-
forms as a general mechanism defining target-tissue sensitiv-
ity to glucocorticoids.
Post-translational modifications
Most proteins undergo post-translational modifications,
which are known to a play role in normal physiological pro-
cesses and the progression of many diseases. Although glu-
cocorticoid receptors are hormone activated transcription
factors, their expression and many of their activities can also
be highly regulated by post-translational modifications,
including phosphorylation, ubiquitination, and sumoylation.
The generation of multiple receptor isoforms by alternative
splicing and alternative translation accompanied by post-
translational modification exponentially increases the com-
plexity in glucocorticoid signaling. Taken together, multiple
processes probably regulate the structure/biological function
of the glucocorticoid receptor.
Protein phosphorylation is a widespread mechanism for
controlling the activity, structure, and cellular localization of
many proteins. One-third of the 100,000 or so proteins in a
typical mammalian cell are thought to be phosphorylated at
any given time (61). Phosphorylation of the glucocorticoid
receptor is an important modification, potentially affecting
the glucocorticoid receptor protein structure, stability, nuclear
localization, and transcriptional activity (62–65). There are
at least six serine residues located in or near the AF-1 tran-
sactivation domain at the N-terminus of the hGR that can be
phosphorylated (S113, S141, S203, S211, S226, and S404)
and eight phosphorylation sites were identified at serines
122, 150, 212, 220, 234, 315, and 412 and at threonine 159
in the mouse glucocorticoid receptor (66, 67). The gluco-
corticoid receptor is partially phosphorylated in the absence
of glucocorticoid; however, phosphorylation increases upon
ligand binding. Several protein kinases such as mitogen-acti-
vated protein kinase (MAPK), cyclin-dependent kinase
(CDK), glycogen synthase kinase-3 (GSK-3), and c-Jun
N-terminal kinase (JNK) (66, 68, 69) are responsible for the
phosphorylation of glucocorticoid receptor and each kinase
has distinct preferences for potential residues.
The phosphorylation status of the glucocorticoid receptor
alters its transcriptional activity at some genes but not others.
For example, mutation of five serine residues did not alter
the ability of glucocorticoid receptor to transactivate a GRE-
TK promoter in COS-7 cells but decreased transcriptional
activity of the glucocorticoid receptor at the GRE-TATA pro-
moter. These data suggest that the role of glucocorticoid
receptor phosphorylation is dependent on the promoter con-
text of the target gene (70). Furthermore, the phosphorylation
status of the glucocorticoid receptor can impact transcrip-
tional activity due to alterations in the recruitment of co-
activators and corepressors. Utilizing a modified yeast
two-hybrid approach, Hittelman and colleagues (71) identi-
fied the tumor susceptibility gene 101 (TSG101) and the
vitamin D receptor-interacting protein 150 (DRIP150) as pro-
teins that interact specifically with a functional glucocorti-
coid receptor AF-1 surface. In yeast and mammalian cells,
TSG101 represses whereas DRIP150 enhances glucocorti-
coid receptor AF-1-mediated transactivation. Thus, the phos-
phorylation status of residues within the AF-1 transactivation
domain can significantly impact cofactor recruitment. As the
D isoform is missing all of the phosphorylation sites
described so far (25), we speculate that phosphorylation
and recruitment of coregulators could contribute to the func-
tional differences observed between the GRa translational
isoforms.
The ubiquitin-proteasome pathway regulates the glucocor-
ticoid signaling system by controlling degradation of the glu-
cocorticoid receptor as well as other molecules in the
cascade. This was first demonstrated in COS-1 cells express-
ing mouse glucocorticoid receptor. Pretreatment of cells with
the proteasome inhibitor MG132 blocked ligand-induced
glucocorticoid receptor degradation and enhanced glucocor-
ticoid receptor transcriptional activity. Mutagenesis of lysine
426, which lies within a candidate PEST degradation motif,
abrogated ligand-dependent glucocorticoid receptor down-
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regulation and enhanced hormone responsiveness (72). GRa
translational isoforms contain the ubiquitination site (K426),
and as predicted there is no difference in the half-lives
among the glucocorticoid receptor isoforms. The half-life of
the GRa isoforms dropped from 12 to 15 h in the absence
of ligand to 6 h in the presence of glucocorticoids (26).
Post-translational modification of the glucocorticoid
receptor can also be accomplished by addition of a small
ubiquitin-related modifier-1 (SUMO-1). Three consensus
sumoylation sites have been identified within the glucocor-
ticoid receptor peptide sequence (K277, K293, and K703).
The first two reside in the N-terminal transactivation region,
whereas the third lies within the ligand-binding domain of
the glucocorticoid receptor. The two N-terminal sites are the
major acceptor sites for SUMO-1 attachment. Mutation of
these sites enhances transcriptional activity of the glucocor-
ticoid receptor on minimal promoters, but has no clear effect
on the more complex mouse mammary tumor virus promoter
(73). Once again, the GR-D isoform (shortest form of the
glucocorticoid receptor) does not contain two of the three
sumoylation sites, suggesting that these sites could also con-
tribute to differences observed among the glucocorticoid
receptor isoforms in cell signaling and biological effects.
Concluding remarks
The therapeutic effects of glucocorticoids have been known
and exploited for more than 60 years. They represent stan-
dard therapy for reducing inflammation and immune acti-
vation in many pathological conditions such as asthma,
rheumatoid arthritis, collagen, vascular, dermatological, and
inflammatory bowel diseases. However, long-term treatment
with glucocorticoids is limited because they induce several
severe side effects. Furthermore, endogenous glucocorticoids
are also implicated in the etiology of other common diseases,
such as hypertension, obesity, type II diabetes, and depres-
sion. With rapid advances in our knowledge of the human
genome, the development of new techniques and the increase
in our understanding of cell signaling, considerable progress
has been achieved in the past decade elucidating the molec-
ular mechanisms that mediate glucocorticoid effects. It
appears that there are multiple mechanisms at each step of
the glucocorticoid receptor signaling cascade through which
target cells alter sensitivity and specificity of the response to
glucocorticoids. A recent discovery by our laboratory sug-
gests that the N-terminal domain of the glucocorticoid recep-
tor substantially contributes to this regulatory diversity. The
GRa isoforms were found to have the ability to regulate a
unique set of genes in response to glucocorticoids and to
selectively regulate apoptosis. In addition, the relative levels
of these isoforms were shown to differ among tissues, sug-
gesting that cellular expression levels and availability of
coactivators and corepressors also influence the transcrip-
tional activity of the glucocorticoid receptor by directly
affecting formation of the transcription initiation complexes
accumulated on target genes promoters. Thus, we propose
another level of regulation in glucocorticoid receptor signal-
ing that involves the expression of a rich repertoire of unique
glucocorticoid receptor isoforms. Owing to the complex pat-
tern of tissue-specific isoform expression, mapping protein
interactions and transactions (such as post-translational mod-
ifications and degradation) within a cell or organism is essen-
tial to developing a molecular understanding of physiology
and to the discovery of new potential therapeutic targets.
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